Camrelizumab Combined With Chemoradiotherapy in Advanced Esophageal Cancer.
This is a prospective single-arm exploratory clinical study. The efficacy and safety of camrelizumab combined with chemoradiotherapy and camrelizumab combined with chemotherapy were evaluated in patients with advanced esophageal cancer who had not previously received any systemic antitumor therapy for esophageal cancer.
Esophageal Neoplasms|Esophageal Diseases|Digestive System Neoplasms
DRUG: camrelizumab|DRUG: Paclitaxel drugs|DRUG: Platinum drug|RADIATION: Radiation
Objective Response Rate(ORR), ORR is determined using RECIST v1.1, defined as best overall response (CR or PR) across all assessment time points during the period from enrolment to termination of trial treatment., 3 years
Overall survival(OS), Defined as the time from the enrollment to death from any cause, 3 years|Progression free survival(PFS), It is defined as the time from enrollment to the first occurrence of disease progression as determined by the investigator with use of RECIST v1.1 or death from any cause, whichever occurs first., 3 years
This is a prospective single-arm exploratory clinical study. The efficacy and safety of camrelizumab combined with chemoradiotherapy and camrelizumab combined with chemotherapy were evaluated in patients with advanced esophageal cancer who had not previously received any systemic antitumor therapy for esophageal cancer.